PEDIATRIC ONCOLOGY GROUP

儿科肿瘤组

• 批准号: 3557302
• 负责人: V M WHITEHEAD
• 金额: $ 7.22万
• 依托单位: MONTREAL CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-01-01 至 1995-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3557302
• 关键词: child (0-11); clinical trials; cooperative study; human subject; human therapy evaluation; pediatric neoplasm /cancer

The Pediatric Oncology Group (POG) is a multi-disciplinary, multi- institutional research community dedicated to finding better treatments for childhood cancer and leukemia. McGill University, a POG founding member, requests support to continue to contribute to all aspects of POG biologic, therapeutic, epidemiologic and evaluative clinical cancer research for the next 5 years. We will enroll the maximum number of patients into multi-modality therapeutic studies of childhood leukemias, lymphomas, solid tumors, and brain tumors; and into non-therapeutic studies of cancer etiology, epidemiology, biology, and late effects of therapy. We are recruiting a satellite, the University of Ottawa, to increase patient accrual, particularly patients with brain tumors. We will comply with IRB ethical requirements and NCI requirements for toxicity reporting and control of restricted drugs. We will continue to participate actively in the administrative, educational and scientific activities of the POG. McGill investigators will continue to contribute to POG science. Acute lymphoblastic leukemia (ALL): Dr. Whitehead has studied tissue delivery of anti-leukemic drugs in two frontline ALL protocols (ALinC 14 and 15). He will test the hypothesis that extent of metabolism of methotrexate in lymphoblasts at diagnosis influences event-free survival in ALL in ALinC 15. New agents and pharmacology: Drs. Bernstein and Whitehead are coordinating a study of Ifosphamide and VP-16 in leukemia (phase I). They will coordinate two phase I studies of Fazarabine in leukemia and in solid tumors. Neuro-oncology: Dr. Freeman will continue to study hyperfractionated radiation therapy in brain stem gliomas. Dr. Baruchel will conduct a phase I study of Acivicin in brain tumors. The University of Ottawa will concentrate initially on the study of brain tumors. Bone marrow transplantation (BMT): Government funding for 4 BMT beds will allow Dr. Koch to enroll many more patients on POG BMT protocols. HIV infection: Dr. Baruchel initiated and is a member of an ad hoc committee to study HIV-associated lymphoma in POG. Neuroblastoma: Dr. Bernstein formed a collaborative group; including POG, to determine whether neuroblastoma can be detected early by screening Quebec newborns for elevated urinary catecholamines. All Quebec children with neuroblastoma, diagnosed clinically or pre-clinically, will be enrolled on POG protocols.

儿科肿瘤组（POG）是一个多学科，多学科， 致力于寻找更好的治疗方法的研究机构 治疗儿童癌症和白血病 麦吉尔大学，POG创始人 成员，请求支持继续为POG的各个方面做出贡献 生物学、治疗学、流行病学和评估性临床癌症 未来五年的研究。 我们将招收最多人数 儿童白血病的多模式治疗研究， 淋巴瘤、实体瘤和脑肿瘤;以及非治疗性 癌症病因学、流行病学、生物学和晚期效应的研究 疗法 我们正在招募一个卫星，渥太华大学， 增加患者增加，特别是脑肿瘤患者。 我们 将遵守IRB伦理要求和NCI要求， 毒性报告和管制受限制药物。 我们将继续 积极参与行政、教育和科学工作 POG的活动。 麦吉尔研究人员将继续为POG科学做出贡献。 急性 淋巴母细胞白血病（ALL）：Whitehead博士研究了组织输送 在两个一线ALL方案（ALinC 14和15）中使用抗白血病药物。 他将检验以下假设： 诊断时的淋巴母细胞影响ALinC中ALL的无事件生存期 15. 新的药物和药理学：伯恩斯坦和怀特黑德博士是 协调异环磷酰胺和VP-16在白血病中的研究（I期）。 他们将协调两项法扎拉滨治疗白血病的I期研究， in solid实体tumors肿瘤. 神经肿瘤学：弗里曼博士将继续研究 脑干胶质瘤超分割放射治疗巴鲁切尔医生 将进行一项关于Acivicin治疗脑肿瘤的I期研究。 大学 渥太华的研究中心将首先集中研究脑肿瘤。 骨 骨髓移植（BMT）：政府资助4个BMT床位， 允许科赫博士在POG BMT方案中招募更多的患者。艾滋病毒 感染：Baruchel博士发起了一个特设委员会， 研究POG中的HIV相关淋巴瘤。神经母细胞瘤：伯恩斯坦博士 成立了一个合作小组;包括POG，以确定是否 通过筛查魁北克新生儿的神经母细胞瘤， 尿中儿茶酚胺升高 所有患有神经母细胞瘤的魁北克儿童， 临床或临床前诊断，将入组POG 协议.